Evidence map›Paper›PMID 39329117›Full record

ArticleFrontiers in pharmacology2024

Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism.

Hailun Xia, Xinhao Xu, Jie Chen, Hualu Wu, Yuxin Shen, Xiaohai Chen, Ren-Ai Xu, Wenzhi Wu

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Hailun XiaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xinhao XuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jie ChenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Hualu WuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yuxin ShenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiaohai ChenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ren-Ai XuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wenzhi WuThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ivacaftor is the first potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein approved for use alone in the treatment of cystic fibrosis (CF). Ivacaftor is primarily metabolized by CYP3A4 and therefore may interact with drugs that are CYP3A4 substrates, resulting in changes in plasma exposure to ivacaftor. The study determined the levels of ivacaftor and its active metabolite M1 by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). We screened 79 drugs and 19 severely inhibited ivacaftor metabolism, particularly two cardiovascular drugs (nisoldipine and nimodipine). In rat liver microsomes (RLM) and human liver microsomes (HLM), the half-maximal inhibitory concentrations (IC

Indexed as

cystic fibrosisdrug-drug interactionivacaftornimodipinenisoldipinepharmacokinetics

Identifiers

PMID39329117
PMCPMC11424460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.